Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries

Table 1 Monitoring frequency based on risk of recurrence[1]

Risk	Monitoring frequency
High-risk tumors	Every 3 to 6 mo for the first 3 yr of adjuvant therapy
	Every 3 mo for 2 yr after stopping adjuvant imatinib, then every 6 mo for 5 yr, then once a year for 5 yr
Low-risk tumors	Every 6 to 12 mo for 5 yr
Very low-risk tumors	Routine follow-up may not be necessary; however, risk of recurrence is not nil